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Abstract
Purpose Radiolabelled glucagon-like peptide 1 (GLP-1)
receptor agonists have recently been shown to success-
fully image benign insulinomas in patients. Moreover, it
was recently reported that antagonist tracers were
superior to agonist tracers for somatostatin and gastrin-
releasing peptide receptor targeting of tumours. The
present preclinical study determines therefore the value
of an established GLP-1 receptor antagonist for the in
vitro visualization of GLP-1 receptor-expressing tissues
in mice and humans.
Methods Receptor autoradiography studies with 125I-GLP-
1(7–36)amide agonist or 125I-Bolton-Hunter-exendin(9–39)
antagonist radioligands were performed in mice pancreas
and insulinomas as well as in human insulinomas;
competition experiments were performed in the presence
of increasing concentration of GLP-1(7–36)amide or
exendin(9–39).
Results The antagonist 125I-Bolton-Hunter-exendin(9–39)
labels mouse pancreatic β-cells and mouse insulinomas,
but it does not label human pancreatic β-cells and
insulinomas. High affinity displacement (IC50 approxi-
mately 2 nM) is observed in mouse β-cells and insulino-
mas with either the exendin(9–39) antagonist or GLP-1
(7–36)amide agonist. For comparison, the agonist 125I-
GLP-1(7–36)amide intensively labels mouse pancreatic
β-cells, mouse insulinoma and human insulinomas; high
affinity displacement is observed for the GLP-1(7–36)amide in
all tissues; however, a 5 and 20 times lower affinity is found for
exendin(9–39) in the mouse and human tissues, respectively.
Conclusion This study reports a species-dependent behaviour
of the GLP-1 receptor antagonist exendin(9–39) that can
optimally target GLP-1 receptors in mice but not in human
tissue. Due to its overly low binding affinity, this antagonist is
an inadequate targeting agent for human GLP-1 receptor-
expressing tissues, as opposed to the GLP-1 receptor agonist,
GLP-1(7–36)amide.
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Introduction
Glucagon-like peptide 1 (GLP-1) receptors are expressed
physiologically in various tissues. The functionally most
prominent among them are the pancreatic islets [1].
GLP-1 receptors have also been found to be overexpressed
in specific human tumours, in particular in insulinomas
[2]. These receptors constitute the molecular basis for
the in vivo targeting of insulinomas using radioactive
GLP-1 agonists such as radiolabelled exendin-3 and
exendin-4 derivatives [3]. This clinical application has
been found particularly useful for the detection and
surgical resection of small benign insulinomas that were
otherwise hardly detectable by established diagnostic
methods [4]. As a future application, it would be
extremely elegant if the same method could be used to
detect in vivo the GLP-1 receptors of the pancreatic islets
in order to assess the β-cell mass in diabetics and other
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patients with diseased, non-neoplastic endocrine pancreas.
However, it may be necessary for adequate β-cell imaging
to have a more sensitive tracer than those presently
available.
It is well known that it is possible to target somatostatin
receptor-expressing tissue with specific radiolabelled somato-
statin receptor agonists [5]. Interestingly, we have
recently observed that sst2 and sst3 tumour labelling
could be significantly improved when radiolabelled
somatostatin receptor antagonists were used instead of
agonists [6]. This observation was also extended to
gastrin-releasing peptide (GRP) receptor targeting with
GRP receptor antagonists [7], suggesting that the phe-
nomenon of targeting peptide receptors with antagonists
may have some generality. Recently, Mukai et al. [8] have
shown that the GLP-1 receptor antagonist 125I-Bolton-
Hunter(BH)-exendin(9–39) was able to visualize pancreatic
islets of the mouse in vivo. Although this study is
extremely promising, more information is required before
entering clinical testing. Indeed, the Mukai et al. study
did not compare the β-cell mass visualization using the
125I-BH-exendin(9–39) antagonist with that using a GLP-1
receptor agonist. It is therefore not known whether this
antagonist is indeed superior to labelling with established
GLP-1-receptor agonists. Moreover, the authors did not
investigate if the antagonist tracer that was working in
mouse tissue would equally work in human GLP-1
receptor-expressing tissues.
The aim of the present study was therefore to evaluate
the binding characteristics of the 125I-BH-exendin(9–39)
antagonist in vitro in comparison to the currently used, well
established agonist 125I-GLP-1(7–36)amide in GLP-1
receptor-expressing tissues in mice and humans, using in
vitro receptor autoradiography. Firstly, this should allow
one to directly compare the antagonist binding properties
with those of the agonist and assess its possible advantages;
secondly, it should allow one to predict whether the
antagonist may be a suitable tracer for human tissues, a
prerequisite before human studies can be started with this
compound.
Materials and methods
Tissues
The following tissues were used for in vitro experiments:
normal mouse pancreas and insulinomas grown in the
Rip1Tag2 mouse model [9] and human insulinomas
surgically resected from patients [4]. These tissues had all
been used and characterized for GLP-1 receptor expression
in previous studies [4, 9]. Informed consent was available
for the human tissue study.
GLP-1 receptor autoradiography
GLP-1 receptor autoradiography was performed as
reported previously [2] using the agonist 125I-GLP-1(7–
36)amide [74 TBq/mmol (2,000 Ci/mmol); Anawa,
Table 1 Binding assay with the 125I-BH-exendin(9–39) antagonist
Tissue Binding affinity (IC50 in nM; mean ±
SEM; n≥3)
GLP-1(7–36)
amide agonist
Exendin(9–39)
antagonist
Mouse pancreatic islets 2.4±0.6 2.6±0.4
Mouse insulinoma 1.9±1.9 2.3±0.4
Human insulinoma Not detectable Not detectable
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Fig. 1 Competition experiments in mouse pancreatic islets and mouse
insulinoma. In both examples, high affinity displacement of the 125I-
BH-exendin(9–39) antagonist tracer by the GLP-1 receptor-selective
agonist GLP-1(7–36)amide (■) and exendin(9–39) antagonist (●) is
illustrated. Mean ± SEM of > 3 independent experiments
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Wangen, Switzerland] or the antagonist 125I-Bolton-
Hunter-exendin(9–39) [74 TBq/mmol (2,000 Ci/mmol);
Anawa, Wangen, Switzerland] as radioligands, used under
identical experimental conditions. The GraphPad Prism
program was used for curve fitting.
Results
Table 1 shows the excellent binding affinities of the GLP-1
receptor agonist GLP-1(7–36)amide and of the exendin
(9–39) antagonist in mouse pancreatic islets and mouse
insulinomas in competition experiments using 125I-BH-
exendin(9–39) antagonist as tracer. Figure 1 shows
competition curves illustrating the almost identical high
affinity displacement of the potent GLP-1 receptor agonist
GLP-1(7–36)amide and the antagonist exendin(9–39) in
these tissues. Table 1, however, also reveals that under
identical conditions no measurable binding of 125I-BH-
exendin(9–39) was detected in the GLP-1 receptor-
expressing human insulinomas.
Table 2 shows the binding affinities of the GLP-1
receptor agonist GLP-1(7–36)amide and the exendin(9–
39) antagonist in mouse pancreatic islets and mouse
insulinomas in competition experiments using the 125I-
GLP-1(7–36)amide agonist tracer. The data resemble the
data obtained with the 125I-BH-exendin(9–39) antagonist
(Table 1), except that the IC50 values for the binding
affinity are found to be approximately five times higher
for the antagonist exendin(9–39) than for the agonist
GLP-1(7–36)amide. This is also illustrated in competi-
tion experiments for mouse pancreatic islets in Fig. 2.
More importantly, Table 2 also shows, surprisingly,
that in human insulinomas the IC50 values for the
exendin(9–39) antagonist is more than 20 times higher
than for the agonist GLP-1(7–36)amide. This is also
illustrated in competition experiments for human insuli-
nomas in Fig. 2.
Figure 3 shows examples of GLP-1 receptor autoradi-
ography which illustrate the above-mentioned observations
on tissue sections. Using the agonist 125I-GLP-1(7–36)
amide as tracer, Fig. 3 shows that all tested tissues,
namely mouse pancreatic islets, mouse Rip1Tag2 insu-
linomas and two different human insulinomas express a
very high density of GLP-1 receptors; the labelling is
completely abolished in the presence of 100 nM GLP-1
(nonspecific binding), indicating the presence of specific
GLP-1 receptors. Conversely, the 125I-BH-exendin(9–39)
antagonist tracer does label the GLP-1 receptors of the
mouse pancreatic islets and mouse insulinomas, albeit
with lower intensity than the agonist tracer. In line with
the above-mentioned competition experiments, it does not
or only very weakly label the GLP-1 receptors in the
human insulinomas, despite the high density of GLP-1
receptors measured with the agonist tracer in these
tissues.
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Fig. 2 Competition experiments in mouse pancreatic islets and
human insulinoma tissues. High affinity displacement of the 125I-
GLP-1(7–36)amide tracer (125I-GLP-1) is observed by the GLP-1
receptor-selective agonist GLP-1(7–36)amide (●) in both tissues,
while the antagonist exendin(9–39) (■) reveals a lower affinity,
especially in the human insulinoma tissues. Mean ± SEM of > 3
independent experiments
Table 2 Binding assay with the 125I-GLP-1(7–36)amide agonist
Tissue Binding affinity (IC50 in nM; mean ±
SEM; n≥3)
GLP-1(7–36)
amide agonist
Exendin(9–39)
antagonist
Mouse pancreatic islets 3.0±0.4 13±1.3
Mouse insulinoma 4.5±1.0 26±4.8
Human insulinoma 3.1±0.4 63±47
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Discussion
The present data indicate that the 125I-BH-exendin(9–39)
antagonist is a good tracer of GLP-1 receptors expressed in
normal and neoplastic pancreatic β-cells in mice tissues.
These data confirm under different conditions and extend to
other systems the findings of Mukai et al. [8]. In addition,
the antagonist exendin(9–39) shows a high affinity competi-
tion comparable to that of the reference GLP-1 receptor
agonist GLP-1(7–36)amide in mice tissues, with an excellent
IC50 value of approximately 2 nM, when
125I-BH-exendin
(9–39) is used as tracer. Conversely, however, our data also
show, most importantly, that the 125I-BH-exendin(9–39)
antagonist is not a good tracer for the labelling of human
GLP-1 receptor-expressing pancreatic tissues: this radio-
labelled antagonist does not label the GLP-1 receptor-
expressing human insulinomas, while under identical
conditions it labels both mice pancreatic β-cells and
insulinomas very well.
The comparison of binding affinities of the exendin
(9–39) antagonist and the GLP-1 receptor agonist using
125I-GLP-1(7–36)amide tracer explains the above-mentioned
results obtainedwith the 125I-BH-exendin(9–39) tracer. While
the binding affinity values for exendin(9–39) tend to be
lower than for GLP-1(7–36)amide in mice, this difference is
markedly higher and reaches approximately a factor of 20
when tested in humans. The high IC50 value of 63 nM for
exendin(9–39) in human insulinomas is therefore the likely
explanation for the failure of in vitro visualization of GLP-1
receptors in this tissue with the antagonist tracer.
Our data indicate that the low binding affinity of the
exendin(9–39) antagonist for human insulinomas is a
sufficient reason to explain the absence of GLP-1 receptor
visualization in these tissues. It gives, however, no clues
as to whether, in general terms, a GLP-1 receptor
antagonist is better or less adequate than a GLP-1
receptor agonist for GLP-1 receptor targeting in humans.
For such a comparison, agonist and antagonist candidates
with similar in vitro and in vivo binding characteristics
should be compared, as was the case in the somatostatin
and GRP receptor targeting studies [6, 7].
The present data are a further example for species
differences related to receptor binding characteristics of
peptide analogs; this was shown previously for other
peptides and more recently for GRP receptor analogs [10].
It indicates the need for including human tissues and human
receptors in the preclinical testing of novel tracer
candidates, either using cell lines expressing the human
receptor or using resected human tumours, as shown in
the present study. Hopefully, future studies will identify
GLP-1 receptor antagonists with radiotargeting characteristics
adequate for human tissue visualization.
Fig. 3 Comparative in vitro GLP-1 receptor autoradiography with the
125I-GLP-1(7–36)amide agonist tracer (125I-GLP-1) and with the 125I-
BH-exendin(9–39) antagonist tracer in mouse tissue (A mouse
pancreatic islets, B mouse insulinoma) and human tissues (C and D
two human insulinomas). Left column: haematoxylin and eosin (HE)-
stained sections with pancreatic islets (arrows) in A (bar=0.1 mm)
and insulinoma tumours in B–D (bars=1 mm). The “total binding”
column with the 125I-GLP-1 agonist shows high density of GLP-1
receptors in mouse pancreatic islets (arrows) and in each of the
insulinoma. The “ns” column represents nonspecific binding in the
presence of 100 nM GLP-1. Conversely, the “total binding” column
with the 125I-BH-exendin(9–39) antagonist shows moderate density of
GLP-1 receptors in mouse pancreatic islets and in mouse insulinoma
but no binding at all in the two human insulinomas. The “ns” column
represents nonspecific binding in the presence of 100 nM GLP-1
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